Perfora will utilise the fund proceeds to scale its online presence
Including the latest fundraising, Perfora has secured more than $3.7 Mn funding to date
Its cap table includes Sauce.VC, Lotus Herbals Family Office, Sara International Family Office and Huddle, among others
Direct-to-consumer (D2C) startup Perfora has secured $2.5 Mn from early-stage consumer VC fund RPSG Capital Ventures.
Perfora will utilise the fund proceeds to scale its online presence with the help of its website and ecommerce marketplaces.
Including the latest fundraising, Perfora has secured more than $3.7 Mn funding to date.
Set up in August 2021 by Jatan Bawa and Tushar Khurana, the Gurugram-based startup sells oral care products including electric toothbrush, probiotic mouthwash, smart flosser, and peroxide-free teeth whitening pen, among others to customers.
“We at RPSG Capital Ventures are committed to supporting companies that use clean label innovation and customer-centricity to create unique solutions that can address consumer problems at scale. This is why we have invested in Perfora that provides science-backed products and creates excitement in the oral care category,” said Abhishek Goenka, head and chief investment officer, RPSG Capital Ventures.
The startup asserts that its toothpaste is Made Safe Certified and does not contain toxic components.
According to the startup, recent studies show that 9 out of 10 adults have a major oral health problem. In India, more than 90% of oral care products have toxic ingredients such as SLS, Titanium Dioxide and Sodium Saccharin etc.
“In our study, it was found that 94% of the people were unaware of the ingredients that are a part of their toothpaste and mouthwash. Yet, 92% of the people found oral health to be equally if not more important than skin health. If consumers were made aware, 76% of the people are not willing to buy items containing potentially harmful ingredients,” said Tushar Khurana, cofounder of Perfora.
Its cap table includes Sauce.VC, Lotus Herbals Family Office, Sara International Family Office and Huddle, among others.
In India, it competes with the likes of Patanjali, Biotique, Listerine and Aravi Organic, among others.
As per a Statista report, the country’s oral care market is pegged at 2023, growing at a CAGR of 3.50% during 2023-27. The Inc42 report states that the country’s D2C segment is expected to grow to $300 Bn by 2030 and expand at a CAGR of 24% during 2021-30.